Humans ; Recurrence ; Stomatitis, Aphthous/therapy*

Because the oral mucositis is often inevitable in acute leukemia patients during chemotherapy, the efforts must be made to keep these leuekmia patients from oral mucositis. So we tried to develop two oral care protocols for reducing the level of oral mucositis during cytotoxic therapy through literature review and our clinical experience. This quasi-experimental study was performed to compare the prohpylatic value of these oral care protocols. Thirty-seven subjects were assigned to one of three groups. The first group performed bivon-normal saline gargling protocol, the second group performed chlorhexidine gargling protocol, and the last contrast group kept traditional gargling protocol, The Oral Assessment Guide(OAG), the Beck's perception of oral comfort, and the discomfort of oral gargling solution were used to assess oral status and subject's oral discomfort during chemotherapy. Each subjects were observed daily from the start of the chemotherapy until Absolute Nertrophil Count (ANC) reached 1,000/mm3. It continued about 2-4 weeks. The data were analyzed by ANCOVA and Kruskal-Wallis oneway ANOVA. The results were as follows : The control group showed significantly highest mean score of the OAG and Beck's perception of oral discomfort among three groups. However the mean score of OAG and Beck's perception of oral discomfort were not significantly different, the bivon saline group showed significantly lowest mean scores among three groups. In conclusion, we recommend that nurses who care acute leukemia patients use bivon-normal saline gargling protocol to reduce the level of oral mucositis during chemotherapy.
Chlorhexidine* ; Drug Therapy* ; Humans ; Leukemia* ; Stomatitis*

Humans ; Stomatitis, Aphthous ; diagnosis ; etiology ; therapy

PURPOSE: Forty percent of the newly diagnosed bladder cancer patients are over the age of 70 years, but it is said that over 75% of them are excluded from active programs of management. This study was to evaluate the usefulness of M-VAC(methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy for invasive bladder cancer patients over the age of 70 years compared with that of patients under the age of 70 years. MATERIALS AND METHODS: Sixty patients with invasive bladder cancer were treated with M-VAC chemotherapy. We divided the patients into group 1- 20 patients over the age of 70 years and group 2- 40 patients under the age of 70 years. We compared cycle length, toxicity and clinical response of M-VAC chemotherapy in group 1 with those of group 2. RESULTS: The Karnofsky performance score was 85.5% in group 1 and 96.3% in group 2. The cycle length needed for 2 cycle of M-VAC chemotherapy was 67.2(range, 56-92) days in Group 1 and 61.5(range, 56-78) days in Group 2(p>0.05). Hematologic toxicities had not significant difference between two groups. Vomiting and stomatitis occurred more common in group 1. In 3 patients of group 1, the serum creatinine level rose to more than 3 mg/dl. The clinical response was 50% in Group 1 and 67% in Group 2(p>0.05). CONCLUSIONS: The bladder cancer patients over the age of 70 years had much more toxicity, longer cycle length and lower response rate, but these differences had not statistical significance. These results suggest that M-VAC chemotherapy in patients over the age of 70 years will achieves the therapeutic effects when the patients have a good physical condition and toxicities to chemotheraphy are monitored closely.
Aged* ; Creatinine ; Doxorubicin ; Drug Therapy* ; Humans ; Stomatitis ; Urinary Bladder Neoplasms* ; Urinary Bladder* ; Vinblastine ; Vomiting

BACKGROUND: Recently, inireaing numbers of chemotherapeutic agens are being used to treat cancer patients. Mucocutaeous complications are commonly sen in association with the administration of these medicaticins. OBJECTIVE: We conducted a study in cancer chemotherapy patient so determine the suspected chemotherapeutic agents ancl frequency of various mucocutaneous side effects in these patients. METHODS: The study involved 140 patients admitted from Decerrae 1993 to September 1994 for cancer chemot herapy at Korea University Guro Hospital. RESULTS: The mucocutaneous side effects during chemotherapy were alopecia(55%), hyperpig mentation(32.9%), stomatitis(20%), phlebitis(12.9%), flushing(8.6%) descending order. Visual grade II, IV alopecia patients were most common, but as the chemot retpy cycle increased so, the severer the alopecia. Although the onset of the alopecia were variake many patients experienced alopcia within 17 to 24 days after the start of chemotherapy. Serpeitie supravenous fluorouracil hyperpigmentation were commor,(17.9%), Diffuse and longitudinal or horizontal band like nail pigmentation were observed, and, pigmented macules were also observei, epecially on the palms and digits. Stomatitis usually developed within 10 days after the start of chemotherapy and it persist ed for about 7 days and the most of the lesions were resolved spor Laeously. Other clinical manifestations accompanied with chmotherapy were tinea infection(16.4%), acne(7.1%), oral thrush (7%), white nail band(4.3%), pruritus(2.9%) in descending order. CONCLUSION: So, physiciars need to be aware of the widely divergnal cutaneous reactions which may occur with the use of antiancer medications.
Alopecia ; Candidiasis, Oral ; Drug Therapy* ; Fluorouracil ; Humans ; Hyperpigmentation ; Korea ; Pigmentation ; Stomatitis ; Tinea

The purpose of this study is to determine the effect of oral cryotherapy on oral mucositis in the patients who receiving high-dose ARA-C plus Mitoxantrone chemotherapy regimen. There were total of ten patients who received the chemotherapy regimen for 13 months ; 5 patients for the experimental group, while the others for the control group. The tool used for assess degree of oral mucositis was the Oral Assessment Guide(OAG) which was developed by Elier, Burger, Peterson in 1988. []The experimental group received oral cryotherapy range from 30minutes before the Mitroxantrone IV infusing to 30minutes after the high-dose ARA-C IV infusing. The control group was not treated by oral cryotherapy. The effect of this treatment was analyzed with the OAG score. The collected data were analysed with, mean, Mann-Whitney U test and Chi-square test according to characteristics of variables. The results were as follows : 1. There were no statistical difference in general characteristics(age, sex, cycle of the chemotherapy, smoking, alcohol) between the two groups, so the homogeneity of two groups was established. There were no differences in the OAG Scores between the two groups statistically. 2. The subjects of this study suffered the neutropenia from 5.6 days to 24.6 days after starting chemotherapy. During the neutropenia period the average OAG scores in the experimental group were lower than that of the control group(experimental group was 9.17+/-1.91, control group was 9.33+/-1.10). 3. The mean OAG of experimental group for 21 days was 204.72+/-20.61, while the mean of control group for 21 days was 206.23+/-15.97. There were, however, no differences between the experimental and the control groups statistically. The subjects of the experimental group expressed more comfortable oral condition than those of the past cycle and they would like to try oral cryotherapy again for the next chemotherapy. The subjects of this study suffered the neutropenia from 5.6 days to 24.6 days after starting chemotherapy. During the neutropenia period the average OAG scores in the experimental group were lower than that of the control group(experimental group was 9.17, control group was 9.33). 5 subjects of the study group complained of numbness, 3 subjects complained of slight headache, and 2 subjects expressed teeth and abdominal discomfort. However, these signs occurred temporarily and were resolved rapidly after cessation of the cryotherapy. It was I recommended that replication with larger sample.
Cryotherapy* ; Cytarabine ; Drug Therapy* ; Headache ; Humans ; Hypesthesia ; Mitoxantrone ; Neutropenia ; Smoke ; Smoking ; Stomatitis* ; Tooth

Oral mucositis continues to be a major complaint of patients who have chemotherapy for the acute leukemia. An innovative and inexpensive remedy which produces favorable results for those afficted is not yet introduced. So we tried to develop two oral care protocols for reducing the level of oral mucositis during cytotoxic therapy through literature review and our clinical experience. The one is sodium bicarbonate-normal saline gargling, and the other consists of chlorhexidine gargling. This quasi-experimental study was performed to compare the efficacy of these two different oral care protocols. Twenty subjects were assigned to one of the two specific diagnosis of leukemia, aim of the chemotherapy. The Oral Assessment Guide(OAG), the Beck's perception of oral comfort, WHO Grading system fot mucositis and the discomfort of oral gargling solution were used to assess oral status and subject's oral discomfort during chemotherapy. Each subjects were observed daily from the start of the chemotherapy until Absolute Neutrophil Count(ANC) reached 1,000. It continued about 2-4 weeks. The data analyzed by Mann-Whittney U test and ANCOVA. The result was follows as: The patient who used sodium bicarbonate-normal saline gargling showed significantly higher mean score of the discomfort of oral gargling solution than chlorhexidine gargling. The other scores were not significantly different between two groups. However the subjects using the sodium bicarbonate-normal saline gargling showed a lower level of oral mucositis. We concluded that oral using sodium bicarbonate-normal saline gargling was between to reduce the level of oral mucositis during chemotherapy and nursing assessments of the oral cavity seemed to promote patient's compliance with the oral care regimen.
Chlorhexidine* ; Compliance ; Diagnosis ; Drug Therapy ; Humans ; Leukemia* ; Mouth ; Mucositis ; Neutrophils ; Nursing Assessment ; Sodium* ; Stomatitis*

Achilles Tendon ; blood supply ; Bloodletting ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Male ; Stomatitis, Aphthous ; therapy

Consensus ; Diagnosis, Differential ; Glucocorticoids ; therapeutic use ; Humans ; Practice Guidelines as Topic ; Recurrence ; Stomatitis, Aphthous ; diagnosis ; therapy

BACKGROUND: Most patients with gastric cancer have metastatic disease at first diagnosis and need palliative chemotherapy. Unfortunately, the response duration of the first line chemotherapy is usually short and most patients need the second line therapy during their disease process. The action mechanism of continuous infusion of 5-FU is different from bolus 5-FU and we can expect that among patients who failed on bolus 5-FU, some patients will achieve response to infusional 5-FU. So, we planned to evaluate the efficacy and safety of leucovorin and infusional 5-FU as a second line regimen for the metastatic gastric cancer refractory to regimen containing bolus 5-FU. METHODS: Patients with recurred or metastatic gastric cancer unresponsive to regimen containing bolus 5-FU were entered into this study. The mixture of 5-FU 1,000 mg/m2/day and leucovorin 50 mg/m2/day was infused continuously for four days and this treatment was repeated by every three weeks. RESULTS: From March, 1996 to July 2001, 25 patients were enrolled in this study. One patient showed a partial remission, 9 stable disease and 15 progressive disease. The overall response rate was 4%. The median time to progression was 73 days and the median duration of overall survival was 140 days. Among total of 92 cycle chemotherapy, leukopenia, granulocytopenia and thrombocytopena of WHO grade 3 or 4 were observed in 7.6%, 12.0% and 14.1%, respectively. Stomatitis, nausea or vomiting of WHO grade 3 or 4 were 13.1%, 5.4%, respectively. Neutropenic infection occurred in two patients. CONCLUSION: The LF regimen was well tolerated with minimal toxicities and showed low effect as the second line chemotherapy for the patients with gastric cancer.
Agranulocytosis ; Diagnosis ; Drug Therapy ; Fluorouracil* ; Humans ; Leucovorin* ; Leukopenia ; Nausea ; Stomach ; Stomach Neoplasms* ; Stomatitis ; Vomiting